Hanmi Pharmaceutical
128940.KS · Bio
Korea's largest pharmaceutical company by revenue. Known for proprietary LAPSCOVERY long-acting platform technology, with multi-billion-dollar global licensing deals in obesity and diabetes therapeutics.
Latest news
Hanmi Pharmaceutical Completes Acquisition of U.S. Biotech Aptose
Hanmi's Second Son Sides With Mother, Sells Stake to Now IB
Hanmi's Lim Jong-hoon Sells 2.5% Holding Company Stake
Hanmi Group Announces Personnel Appointments
Nature Names Hanmi, SK Biopharm as Innovation Leaders in K-Bio
Hanmi Group Promotes Six Executives in Performance-Focused Reshuffle
Hanmi Science's Top Shareholder Shin Seeks 300 Billion Won for Stake Battle
Hanmi Unveils Obesity Drug That Builds Muscle While Cutting Weight
Hanmi Pharmaceutical Unveils Muscle-Building Obesity Drug at ADA 2026
Alteogen Wins European Patent for SC Formulation as Hanmi, Oscotec Seal Trillion-Won Licensing Deals
Hanmi Pharmaceutical Fuels Hopes for More Licensing Deals This Year
K-Bio Targets Next-Generation Obesity Treatments at ADA 2026
Hanmi Pharmaceutical Seals First Big Deal in 6 Years With Lilly Licensing Pact
Hanmi Pharmaceutical Licenses GLP-2 Drug Candidate to Eli Lilly in $1.26 Billion Deal
Corporate Disclosures
Eli Lilly Bets 1.9 Trillion Won on Hanmi's GLP-2 Drug
Hanmi Pharm Surges 13% on $1.26 Billion Eli Lilly Licensing Deal
Hanmi Pharmaceutical Unveils First Research on Muscle-Boosting Obesity Drug
Korean Pharma Firms Race to Adopt AI Across Drug Development
Hanmi Pharmaceutical Partners with Organon to Export Combination Drugs to Southeast Asia
Korean Pharma Firms Race Toward Phase 3 Trial Results for Key Drugs
Hanmi Pharmaceutical Expands Obesity Drug Indication to Diabetes, Begins Phase 3 Dosing
